BRCA1 and breast cancer: Indeed, there was one case of a patient in our cohort with breast cancer and a reversion mutation in BRCA1, with no documented history of having received either a PARP inhibitor or a platinum-based therapy, the two classes of therapy that have been associated with reversion alterations due to their role in capitalizing on the DNA damage repair pathway.